腾盛博药在2025年亚太肝病学会年会(APASL)上公布其正在进行的2期ENSURE研究的新数据,表明BRII-179有望通过目标患者识别提高HBsAg清除率 Brii biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. Brii biosciences limited (“brii bio”, stock code 2137.hk) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas.
OPEN